- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02272634
A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients
A Randomized, Double-Blind, Placebo Controlled, Multicenter 2a Study to Assess Safety, Daily Respiratory Symptoms, PK, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe COPD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Treatments are described as follows:
Treatment A: Multiple oral YPL-001 80 mg doses (1 x 80 mg tablet + 1 x 1 YPL-001 80 mg matching placebo tablet) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days. Only the morning dose will be administered on Day 56.
Treatment B: Multiple oral YPL-001 160 mg doses (2 x 80 mg tablets) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days. Only the morning dose will be administered on Day 56.
Treatment C: Multiple oral matching placebo (2 x 1 YPL-001 80 mg matching placebo tablets) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days. Only the morning dose will be administered on Day 56. In all treatments, one tiotropium (Spiriva® HandiHaler®) 18 μg capsule will also be administered QD every morning prior to study drugs administration. Albuterol will be administered on an as needed basis. Each dose of Treatments A, B and C will be administered orally with approximately 240 mL of water.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- UAB Lung Health Center
-
-
Florida
-
Winter Park, Florida, United States, 32789
- Florida Pulmonary Research Institute, LLC
-
-
Ohio
-
Columbus, Ohio, United States, 43213
- Aventiv Research Inc.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 191140
- Temple Lung Center, Temple University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult males and/or females, 30 to 85 years of age (inclusive).
- History of COPD for at least 12 months prior to screening.
- Diagnosed with COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines with symptoms compatible with COPD for at least 12 months prior to screening.
- Classified as moderate to severe COPD based on the current severity classification GOLD Stage 2-3 disease in terms of post-bronchodilator spirometry at screening
- etc.
Exclusion Criteria:
- History of life-threatening COPD including respiratory arrest, intensive care unit admission and/or requiring intubation.
- History of more than 2 hospitalizations for COPD within 12 months prior to screening.
- Presentation of an acute exacerbation of COPD that will be associated with increase sputum volume or change in sputum color within 4 weeks before Day 1 of the Run-in Period.
- Evidence of pulmonary heart disease, or clinically significant pulmonary hypertension.
- etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A
Multiple oral YPL-001 80 mg doses (1 x 80 mg tablet + 1 x 1 YPL-001 80 mg matching placebo tablet) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
|
twice daily [BID]
Other Names:
|
Experimental: Treatment B
Multiple oral YPL-001 160 mg doses (2 x 80 mg tablets) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
|
twice daily [BID]
Other Names:
|
Placebo Comparator: Treatment C
Multiple oral matching placebo (2 x 1 YPL-001 80 mg matching placebo tablets) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days.
|
twice daily [BID]
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-Emergent Adverse Event Frequency by Treatment - Number of Patients Reporting Events
Time Frame: Up to Day 56
|
A TEAE was defined as an AE that was starting or worsening at the time of or after study drug administration.
All AEs collected by the clinics and recorded in the CRF were captured in the database and were listed in by-patient data listings.
|
Up to Day 56
|
Treatment-Emergent Adverse Event Frequency by Treatment - Adverse Events
Time Frame: Up to Day 56
|
A TEAE was defined as an AE that was starting or worsening at the time of or after study drug administration.
All AEs collected by the clinics and recorded in the CRF were captured in the database and were listed in by-patient data listings.
|
Up to Day 56
|
Treatment-Emergent Adverse Event Frequency by Treatment, Severity, and Relationship to Drug - Number of Patients Reporting Events
Time Frame: Up to Day 56
|
When a patient experienced the same AE at more than one level of severity, the patient was counted once under the highest severity.
|
Up to Day 56
|
Treatment-Emergent Adverse Event Frequency by Treatment, Severity, and Relationship to Drug - Adverse Events
Time Frame: Up to Day 56
|
When a patient experienced the same AE at more than one level of severity, the patient was counted once under the highest severity.
|
Up to Day 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Main Peak Expiratory Flow (PEF) Measured Daily
Time Frame: Baseline to Day 55
|
The PEF assessments are made daily prior to each dose from Day 1 of the Run-in Period to Day 56 of the Treatment Period.
Three measurements were made at each time point using a hand held PEF meter.
Readings not performed in the clinical research unit (CRU) were recorded in the patient e-diary.
All PEF assessments were performed before administration of a bronchodilator where possible.
Baseline is Day 1 predose measurement.
|
Baseline to Day 55
|
Change From Baseline of Symptom Severity Score for Symptoms of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
Time Frame: Baseline to Day 55
|
Patient is asked to record the major (sputum quality, color, consistency) and minor (cough, wheeze, sore throat, nasal congestion, discharge, and body temperature above 100°F) symptoms of COPD exacerbation via the e-diary before each dosing. Baseline is Day 1 predose measurement
Symptom score catecorizes normal(0-0.5), mild(1-1.5), moderate(2-2.5), severe(3-3.5) |
Baseline to Day 55
|
Change From Baseline in Dyspnea (Modified Borg Dyspnea Scale)
Time Frame: Baseline to Day 55
|
Severity level of patient's dyspnea is accessed via the modified Borg dyspnea scale programmed within the e-diary.
The modified Borg dyspnea scale is a self-administered categorical scale with a score from 0 to 10, where 0 (as a measure of dyspnea) corresponds to the sensation of normal breathing (absence of dyspnea) and 10 corresponds to the patient's maximum possible sensation of dyspnea.
|
Baseline to Day 55
|
Change From Baseline of Calculated Score From Duke Activity Status Index (DASI)
Time Frame: Baseline to Day 55
|
Patient's functional capacity and activity status were accessed via the DASI programmed within the e-diary. DASI is a self-administered 12-item questionnaire that assesses daily activities such as personal care, ambulation, household tasks, sexual function and recreation with respective metabolic costs. Each item has a specific weight based on the metabolic cost. The final score ranges between 0 and 58.2 points. The higher score shows the better the functional capacity. |
Baseline to Day 55
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Time Frame: Baseline (Screen) to Day 55
|
Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second.
FEV1 is measured by spirometry performed at approximately the same time of day on each visit to avoid diurnal variation.
A positive change from baseline in FEV1 indicates improvement in lung function.
|
Baseline (Screen) to Day 55
|
Change From Baseline in Inspiratory Capacity (IC)
Time Frame: Baseline (Screening) to Day 55
|
Inspiratory capacity (IC) is the maximum volume of air that can be inhaled into the lungs from the normal resting position after breathing out normally.
IC is measured by spirometry performed at approximately the same time of day on each visit to avoid diurnal variation.
|
Baseline (Screening) to Day 55
|
Change From Baseline in Forced Expiratory Volume in 1 Second/Forced Vital Capacity (FEV1/FVC) Ratio
Time Frame: Baseline to Day 55
|
The ratio is calculated as the amount of air expelled from the lungs in one second after a full inspiration (FEV1) divided by the volume of air that can forcibly be blown out after a full inspiration (FVC).
|
Baseline to Day 55
|
Transition Dyspnea Index (TDI) Focal Score
Time Frame: Baseline to Day 55
|
Dyspnea at baseline (Day -1) will be assessed with the Baseline Dyspnea Index (BDI).
This instrument has 3 domains (functional impairment, magnitude of task and magnitude of effort) with the values added for a combined focal score.
Functional impairment determines the impact of breathlessness on the ability to carry out activities; magnitude of task determines the type of task that causes breathlessness, magnitude of effort establishes the level of effort that results in breathlessness.
The BDI scores range from 0 (very severe impairment) to 4 (no impairment) for each domain with the baseline focal score consisting of the sum of each domain (0 to 12).
Dyspnea throughout the study will be performed at the time points.
The change from baseline is measured by the Transition Dyspnea Index (TDI) score which ranges from -3 (major deterioration) to +3 (major improvement) for each domain with the TDI focal score consisting in the sum of each domain (-9 to +9).
|
Baseline to Day 55
|
Change From Baseline in Chronic Obstructive Pulmonary Disease Assessment Test (CAT)
Time Frame: Baseline to Day 55
|
The chronic obstructive pulmonary disease assessment test (CAT) is a short and simple questionnaire of 8 items completed by patients to be performed at the time points.
Scores for each of the 8 items are summed to give a single, final score ranging from 0 (no impact on daily activities) to 40 (very high impact on daily activity).
|
Baseline to Day 55
|
Change in Percentage of Total Cells in Bronchoalveolar Lavage (BAL)
Time Frame: Baseline (Day -1) and Day 55
|
The bronchoalveolar lavage (BAL) samples were collected at baseline and again at the completion of the study for pharmacodynamics (PD) assessments of biomarkers.
BAL samples are at analyzed for total cell count (cells/mL) of white blood cell, macrophages, lymphocytes, neutrophils, and eosinophils as a percentage of total cells.
|
Baseline (Day -1) and Day 55
|
Change in Concentrations of Inflammatory Marker in Bronchoalveolar Lavage (BAL)
Time Frame: Baseline (Day -1) and Day 55
|
The bronchoalveolar lavage (BAL) samples are collected at baseline and again at the completion of the study for pharmacodynamics (PD) assessments of biomarkers.
BAL samples are analyzed for concentrations of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-8, IL-13, Myeloperoxidase (MPO), neutrophil elastase (ELA2), monocyte chemotactic protein-1 (MCP-1), myeloperoxidase(MPO), and matrix metalloproteinase-9 (MMP-9).
|
Baseline (Day -1) and Day 55
|
Change in Percentage of Total Cells in Blood
Time Frame: Baseline to Day 55
|
The blood samples are collected at the the time points of the study for pharmacodynamics (PD) assessments of biomarkers.
The blood samples are analyzed for inflammatory markers (total and differential cell counts as absolute and percentage for neutrophils, macrophages, eosinophils and lymphocytes).
|
Baseline to Day 55
|
Change in Concentrations of Inflammatory Marker in Plasma/Blood
Time Frame: Baseline to Day 55
|
The blood samples are collected at the the time points of the study for pharmacodynamics (PD) assessments of biomarkers.
The blood samples are analyzed for concentrations of C-reactive protein (CRP), fibrinogen, TNF-α, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-13, MCP-1, and MMP-9.
Baseline is Day 1 predose measurement.
|
Baseline to Day 55
|
Number of Participants With COPD Exacerbation
Time Frame: Baseline to Day 56
|
Number of COPD exacerbation during 8-week treatment.
COPD exacerbations are defined as a new onset or worsening of at least one respiratory symptom (i.e.
dyspnea, cough, sputum purulence or volume, or wheeze) present for at least 3 consecutive days, documented change or increase in COPD-related treatment due to worsening symptoms or documented COPD-related hospitalizations or emergency room visits.
|
Baseline to Day 56
|
Change From Baseline in Forced Vital Capacity (FVC)
Time Frame: Baseline (Screen) to Day 55
|
Forced vital capacity (FVC) is the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible.
FVC is measured by spirometry performed at approximately the same time of day on each visit to avoid diurnal variation.
A positive change from baseline in FVC indicates improvement in lung function.
|
Baseline (Screen) to Day 55
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark T Dransfield, MD, The Kirklin Clinic of Uab Hospital
- Principal Investigator: Gerard J Criner, MD, Temple University
Publications and helpful links
General Publications
- Lee SU, Lee S, Ro H, Choi JH, Ryu HW, Kim MO, Yuk HJ, Lee J, Hong ST, Oh SR. Piscroside C inhibits TNF-alpha/NF-kappaB pathway by the suppression of PKCdelta activity for TNF-RSC formation in human airway epithelial cells. Phytomedicine. 2018 Feb 1;40:148-157. doi: 10.1016/j.phymed.2018.01.012. Epub 2018 Jan 31.
- Ryu HW, Lee SU, Lee S, Song HH, Son TH, Kim YU, Yuk HJ, Ro H, Lee CK, Hong ST, Oh SR. 3-Methoxy-catalposide inhibits inflammatory effects in lipopolysaccharide-stimulated RAW264.7 macrophages. Cytokine. 2017 Mar;91:57-64. doi: 10.1016/j.cyto.2016.12.006. Epub 2016 Dec 21.
- Lee SU, Sung MH, Ryu HW, Lee J, Kim HS, In HJ, Ahn KS, Lee HJ, Lee HK, Shin DH, Lee Y, Hong ST, Oh SR. Verproside inhibits TNF-alpha-induced MUC5AC expression through suppression of the TNF-alpha/NF-kappaB pathway in human airway epithelial cells. Cytokine. 2016 Jan;77:168-75. doi: 10.1016/j.cyto.2015.08.262. Epub 2015 Aug 28.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- YPL-001_YJP-130403
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on YPL-001 80 mg
-
Genencell Co. Ltd.Recruiting
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
Allist Pharmaceuticals, Inc.Not yet recruiting
-
IpsenRecruitingPrimary Sclerosing CholangitisUnited States, Spain, Germany, Canada, United Kingdom, Italy, Portugal
-
AstraZenecaActive, not recruitingStage IB-IIIA Non-small Cell Lung CarcinomaUnited States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
-
IpsenRecruitingPrimary Biliary Cholangitis (PBC)United States, Spain, Romania
-
TakedaCompleted
-
Viridian Therapeutics, Inc.Not yet recruitingThyroid Eye DiseaseUnited States
-
Aevi Genomic Medicine, LLC, a Cerecor companyCompletedAttention Deficit Disorder With HyperactivityUnited States